Merck (France)

Recent papers from Merck (France)

1. Micro- and nanoplastics in food and water from farm-to-fork: exposure pathways, human biomonitoring and AI-enhanced detection – a systematic reviewnpj Science of Food · 2026
2. Cognitive Resilience and Improvements in Health-Related Quality of Life Over 4 Years in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Results from the CLARIFY-MS Extension StudyMultiple Sclerosis and Related Disorders · 2026
3. Applying Raman Spectroscopy for Real-Time Monitoring of Ultra- and Diafiltration Steps in Viral Vector PurificationPharmaceutics · 2026
4. Real-world treatment sequences and outcomes in recurrent/metastatic head and neck squamous cell carcinoma in France (TERENCE study)Oral Oncology · 2026
5. A multi-outcome prognostic score for therapeutic responses in multiple sclerosisRevue Neurologique · 2026
6. A Qualitative Study of Lived Treatment Experiences and Preferences of Long-Term DMT Users with Relapsing–Remitting Multiple SclerosisNeurology and Therapy · 2026
7. Improved methodology for direct monitoring of large‐scale manufacturing cell culture using Raman spectroscopy data from process developmentBiotechnology Progress · 2026
8. Overview of working conditions in pharmacy technology units: A professional evaluation in five French healthcare institution.2026
9. International Expert Opinion on Optimal Switching to Cladribine Tablets from Other High-Efficacy Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis: Opportunities and ChallengesNeurology and Therapy · 2026
10. P-1185. Healthcare Resource Utilization (HCRU) of Critical Care Patients by Rank of Initiation from the Study of Prescribing patterns and Effectiveness of Ceftolozane/Tazobactam: Real-world Analysis (SPECTRA)Open Forum Infectious Diseases · 2026
11. Evaluating MRI-Confirmed Relapses as a Novel Primary Endpoint in Multiple Sclerosis Trials2025
12. Privacy-by-Design Approach to Generate Two Virtual Clinical Trials for Multiple Sclerosis and Release Them as Open Datasets: Evaluation StudyJournal of Medical Internet Research · 2025
13. Precemtabart tocentecan, an anti-CEACAM5 antibody–drug conjugate, in metastatic colorectal cancer: a phase 1 trialNature Medicine · 2025
14. Long-Term Management and Therapeutic Sequencing for Patients with Relapsing Multiple Sclerosis in France: A Vignette StudyNeurology and Therapy · 2025
15. MOMENT registry: Patients with advanced non-small-cell lung cancer harboring MET exon 14 skipping treated with systemic therapyJournal of Comparative Effectiveness Research · 2025
16. Patient preferences on pen injectors for assisted reproductive technology: a discrete choice experiment in FranceExpert Opinion on Drug Delivery · 2024
17. Real-world Study of Avelumab First-line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma in France: Overall Results from the Noninterventional AVENANCE Study and Analysis of Outcomes by Second-line TreatmentEuropean Urology Oncology · 2024
18. Are we in a Big Data era for multiple sclerosis? Lessons from integrating clinical trials and observational studies data into the PRIMUS precision medicine platform2024
19. Privacy-by-design generation of two virtual clinical trials in multiple sclerosis and their release as open datasets2024
20. Privacy-by-design generation of two virtual clinical trials in multiple sclerosis and their release as open datasets2024